Selvita to Release the Most Recent Results from its Oncology Programs at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
|| Print ||
|Monday, 24 October 2011 11:15 (UTC + 2)|
Krakow, Poland, October 24, 2011 / B3C newswire / - Selvita, Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS and oncology disorders, as well as provision of non-clinical research services, announced today that data from two of its oncology programs is scheduled to be reported at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, November 12-16, 2011, in San Francisco, CA, USA.
Data presented during this conference will include new results from the SEL24 program, a group of specific inhibitors of Pim-1 kinase, as well as the first data from SEL120 program, a potentially first in class kinase inhibitor.
A poster presentation entitled "Novel Pim kinase inhibitors for treatment of hematological malignancies and solid tumors" is scheduled to be presented at the poster session A, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 1" on Sunday, November 13th, 2011 from 12:30 PM - 2:30 PM, at the West Hall, Level One, Moscone Center West (Abstract #: A243)
A poster presentation entitled "Antitumor activity of SEL120: An orally available small-molecule inhibitor of Haspin kinase, for standalone and combination therapy with AuroraB inhibitors in colorectal cancer" is scheduled to be presented at the poster session B, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 2" Monday, November 14th, 2011 from 12:30 PM - 2:30 PM, at the West Hall, Level One, Moscone Center West (Abstract # B242).
“Current and further development of both SEL24 and SEL120 program, presented at the AACR-EORTC-NCI conference, was made possible thanks to the substantial investment received by Selvita through private placement and the debut on the NewConnect market in July 2011– said Dr Nicolas Beuzen, Selvita’s Chief Scientific Officer. SEL24 is currently at the lead optimization stage, with first clinical trials to be initiated in 2012, while SEL120 is currently in the early phase of discovery research. Selvita’s strategy assumes sales of both programs, SEL24 in 2012 and SEL120 in the following years, which will allow the company to break-even in 2012.”